Teijin Pharma, Sato Pharmaceutical Jointly Introduce Antipsoriatic Agent Bonalfa.Tokyo, Japan, June 26, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Teijin Pharma and Sato Pharmaceutical jointly announced on June 26 that they will begin marketing Bonalfa High Lotion 20 mu-g/g (tacalcitol), an ethical agent for treating psoriasis vulgaris, on June 27. Bonalfa High Lotion is a new formulation of Bonalfa High Ointment ointment /oint·ment/ (oint´ment) a semisolid preparation for external application to the skin or mucous membranes, usually containing a medicinal substance. oint·ment n. , which is currently co-promoted by the two companies. Tacalcitol, which was initially discovered by Teijin Pharma, is activated vitamin D vitamin D Any of a group of fat-soluble alcohols important in calcium metabolism in animals to form strong bones and teeth and prevent rickets and osteoporosis. It is formed by ultraviolet radiation (sunlight) of sterols (see steroid) present in the skin. 3. Indicated for the treatment of keratosis keratosis /ker·a·to·sis/ (ker?ah-to´sis) pl. kerato´ses any horny growth, such as a wart or callosity.keratot´ic actinic keratosis , Tacalcitol is available for sale in about 30 countries worldwide. The two companies aim to generate a combined total of 800 million yen (US$7.0 mil) in sales per year three to four years from now. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion